Literature DB >> 26719135

Feasibility of Spectral Domain Optical Coherence Tomography Acquisition Using a Handheld Versus Conventional Tabletop Unit.

Nicole Mendez1, Natasha V Nayak2, Anton M Kolomeyer3, Ben C Szirth1, Albert S Khouri4.   

Abstract

PURPOSE: Patients afflicted with ocular complications of diabetes represent a diverse demographic who often cannot undergo spectral-domain optical coherence tomography (SD-OCT) imaging of the retina due to postural restraints. Our pilot study compared imaging acquisition methods using SD-OCT in the handheld (HH) mode versus the conventional tabletop (TT) method.
METHODS: Our study included 22 undilated eyes of 22 subjects (mean ± SD age, 35.8 ± 16.8 years) imaged using HH and TT iVue SD-OCT (Optovue, Fremont, CA). Statistical analysis was performed using Microsoft Excel 12.2.7 (Microsoft Corporation, Redmond, WA) software with an accepted significance of P < .05.
RESULTS: Strong intraclass correlation coefficient was observed for (1) overall (.97), superior (.93), and inferior (.94) ganglion cell complex thickness, and (2) central (.98), inferior (.90), superior (.92), nasal (.94), and temporal (.93) macular retinal thickness. Mean scan quality index was adequate but lower in HH versus TT SD-OCT (62.8 vs 68.1, respectively; P < .0001). Multiple attempts for adequate imaging were required more frequently in HH versus TT SD-OCT (34% vs 5%, respectively; P < .001).
CONCLUSION: HH SD-OCT may be a feasible alternative to TT SD-OCT in select situations, especially in patients suffering from diabetic complications with limited mobility.
© 2015 Diabetes Technology Society.

Entities:  

Keywords:  diabetes; imaging methods; macula/fovea; optical coherence tomography

Mesh:

Year:  2015        PMID: 26719135      PMCID: PMC4773977          DOI: 10.1177/1932296815624712

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  24 in total

Review 1.  Complications of type 1 diabetes.

Authors:  L Yvonne Melendez-Ramirez; Robert J Richards; William T Cefalu
Journal:  Endocrinol Metab Clin North Am       Date:  2010-09       Impact factor: 4.741

2.  Reproducibility of and effect of magnification on optical coherence tomography measurements in children.

Authors:  Xiu Ying Wang; Son C Huynh; George Burlutsky; Jenny Ip; Fiona Stapleton; Paul Mitchell
Journal:  Am J Ophthalmol       Date:  2006-12-22       Impact factor: 5.258

3.  Rising incidence of insulin dependent diabetes in children aged under 5 years in the Oxford region: time trend analysis. The Bart's-Oxford Study Group.

Authors:  S G Gardner; P J Bingley; P A Sawtell; S Weeks; E A Gale
Journal:  BMJ       Date:  1997-09-20

4.  Standards of medical care in diabetes--2010.

Authors: 
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

5.  Hand-held spectral domain optical coherence tomography finding in shaken-baby syndrome.

Authors:  Rajeev H Muni; Radha P Kohly; Elliott H Sohn; Thomas C Lee
Journal:  Retina       Date:  2010-04       Impact factor: 4.256

6.  Handheld optical coherence tomography scanner for primary care diagnostics.

Authors:  Woonggyu Jung; Jeehyun Kim; Mansik Jeon; Eric J Chaney; Charles N Stewart; Stephen A Boppart
Journal:  IEEE Trans Biomed Eng       Date:  2010-12-03       Impact factor: 4.538

7.  Patterns of diabetic macular edema with optical coherence tomography.

Authors:  T Otani; S Kishi; Y Maruyama
Journal:  Am J Ophthalmol       Date:  1999-06       Impact factor: 5.258

8.  Spectral domain optical coherence tomography for glaucoma (an AOS thesis).

Authors:  Joel S Schuman
Journal:  Trans Am Ophthalmol Soc       Date:  2008

9.  Imaging the infant retina with a hand-held spectral-domain optical coherence tomography device.

Authors:  Adrienne W Scott; Sina Farsiu; Laura B Enyedi; David K Wallace; Cynthia A Toth
Journal:  Am J Ophthalmol       Date:  2008-10-09       Impact factor: 5.258

Review 10.  Amputation in diabetic patients.

Authors:  Hendrik Van Damme; Raymond Limet
Journal:  Clin Podiatr Med Surg       Date:  2007-07       Impact factor: 1.231

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.